CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cordex Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cordex Pharma Inc
470 Nautilus Street, Suite 300
Phone: (858) 551-5700p:858 551-5700 La Jolla, CA  92037  United States Fax: (267) 551-5704f:267 551-5704
On 10/27/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Cordex Pharma Inc for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
Cordex Pharma, Inc. (Cordex), formerly Duska Therapeutics, Inc., is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5’-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation, of which constitute therapeutic modalities for the treatment of cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development, which are ATPace and CDP 1050. In addition, Cordex has a preclinical program to develop new chemical entities that target a discovered pathway in the pathophysiology of chronic obstructive pulmonary disease.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200912/31/2008YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Scientific Officer AmirPelleg 66 8/1/2004 8/1/2004
Chief Executive Officer, Director Shepard M.Goldberg 55 2/1/2010 10/1/2007
Director Manuel F.Graiwer 68 6/1/2007 6/1/2007
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Cordex Pharma Inc
Cordex Pharma, Inc.
Duska Therapeutics Inc.
DUSKA THERAPEUTICS, INC.
SHIPROCK INC

General Information
Stock Exchange: OTC
Federal Tax Id: 860982792
Fax Number: (267) 551-5704


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023